Wedbush analyst David Nierengarten initiated coverage of Bicara Therapeutics (BCAX) with an Outperform rating and $31 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAX: